Abstract
Understanding of neuroendocrine tumors has increased greatly in the last 2 decades. Along with this, the prevalence of neuroendocrine tumors has increased because of the ubiquitous use of cross-sectional imaging, improved endoscopic screening, and the indolent nature of the disease. Up to 35% of patients have symptoms at the time of diagnosis, whereas the others have occult disease. Neuroendocrine tumors are a diverse group of malignancies with unique clinical courses. This article critically reviews the most important randomized controlled trials for neuroendocrine tumors and introduces a few awaiting completion.
Original language | English (US) |
---|---|
Pages (from-to) | 751-765 |
Number of pages | 15 |
Journal | Surgical Oncology Clinics of North America |
Volume | 26 |
Issue number | 4 |
DOIs | |
State | Published - Oct 2017 |
Keywords
- Carcinoid
- Clinical trial
- Neuroendocrine tumor
- Somatostatin
ASJC Scopus subject areas
- Surgery
- Oncology